ArticleThe Pan African medical journal2024
Evaluation of the antihyperglycemic and antihyperlipidemic effects of
Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: diabetes mellitus is a metabolic disease of the endocrine system characterized by elevated blood sugar levels due to disorders in insulin action, and secretion. This study aims to evaluate the antihyperglycemic and antihyperlipidemic effects of Trigonella foenum-graecum L and Coffea arabica L seeds in STZ (streptozotocin) induced diabetic mice: impact on kidney and liver functions. Methods: twenty-six male mice aged 2 weeks, were divided into five groups: normal control, diabetic control (DC), positive control (PC), galactomannan-treated (GM), and chlorogenic acid-treated (CGA). Trigonella foenum-graecum L (TFL) seeds were bought from the local market. Similarly, Coffea arabica L (CAL) seeds were collected from the Ethiopian Commodity Exchange. After a 28-day treatment period TFL and CAL, Fasting Blood Glucose diabetic control (FBG], Oral Glucose Tolerance (OGT), lipid profile, and kidney and liver function tests were conducted. Statistical analysis was performed using R software, with the significance level set at a P-value < 0.05. Results: galactomannan-treated and CGA significantly reduced FBG by -176.8 and -252.4 (p<0.01), respectively, and improved OGT (AUC of CGA-7449 and GM-14754) in comparison to DC (52452] (p<0.05). Similarly, liver and kidney function tests showed a statistically significant difference against the non-treated group 1 (p<0.01). In the lipid profile test, galactomannan reduced triglyceride and cholesterol levels, while chlorogenic acid improved low-density lipoprotein and cholesterol. Conclusion: according to this research, TFL and CAL seeds decreased fasting blood glucose levels and improved glucose tolerance, lipid profiles, liver and kidney function tests, and glucose tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.